profit from every $100 of sales.
$0$100
Caribou Biosciences
$0.36-4.81% today
-81.8% in 1 year
1-year low $0.361-year high $2.43
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Caribou Biosciences sold, what it kept, and what it did with the cash.
Sales went from $13.9 million in 2022 to $11.2 million in 2025, with -$148 million of profit last year.
SalesProfit
Caribou Biosciences vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Caribou Biosciences | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Caribou Biosciences's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 14 | 34 | 10 | 11 | |
| – | – | – | – | |
| -106 | -116 | -167 | -136 | |
| -105 | -113 | -163 | -133 | |
| -99 | -102 | -149 | -148 | |
| -1.64 | -1.38 | -1.65 | -1.59 | |
| – | – | – | – | |
| -768.2% | -336.6% | -1,667.2% | -1,220.5% | |
| -717.8% | -296.1% | -1,491.9% | -1,327.4% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 374 | 432 | 313 | 175 |
| Cash | 58 | 51 | 16 | 12 |
| Total debt | 28 | 27 | 26 | 27 |
| Total liabilities | 73 | 64 | 60 | 53 |
| 301 | 368 | 253 | 122 | |
| 61 | 74 | 90 | 93 | |
| -25.6% | -23.2% | -47.1% | -72.0% | |
| -33.0% | -27.7% | -58.9% | -121.2% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -91 | -93 | -138 | -111 | |
| 7 | 12 | 7 | 1 | |
| -98 | -105 | -145 | -112 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 12 | 14 | 17 | 13 |
Valuation
- –
- –
- –
- 1.9×
- 3.5×
- –
- –
- -287.4%
- -378.9%
- 0.0%
Profitability
- 94.2%
- -1,220.5%
- -1,327.4%
- -1,039.3%
- -100.4%
- -45.2%
- -100.1%
- -89.4%
- -101.8%
- 843.7%
Growth
- −7.0%
- –
- +22.4%
- –
- +11.6%
Financial health
- –
- 0.26
- 18.1%
- –
- 6.22
- 6.22
- 0.08
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 9%of 867
What analysts expect
- Average price target
- $5.00
- Range
- $3.00 – $7.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -0.26 | -0.33 | +21.2% |
| Mar 5, 2026 | -0.28 | -0.33 | +15.2% |
| Nov 12, 2025 | -0.30 | -0.36 | +16.7% |
| Aug 12, 2025 | -0.35 | -0.40 | +12.5% |
| May 8, 2025 | -0.43 | -0.43 | +0.0% |
| Mar 10, 2025 | -0.39 | -0.40 | +2.5% |
| Nov 6, 2024 | -0.38 | -0.44 | +13.6% |
| Aug 6, 2024 | -0.42 | -0.45 | +6.7% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
40No pass
Benjamin Graham
59No pass
Philip Fisher
47No pass
Peter Lynch
38No pass
Joel Greenblatt
2No pass
Charlie Munger
51No pass
Terry Smith
48No pass
Questions about Caribou Biosciences
Is Caribou Biosciences a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Caribou Biosciences AI analysis
What does Caribou Biosciences do?
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. It is in Biotechnology.
Does Caribou Biosciences pay a dividend?
No. Caribou Biosciences does not pay a dividend at the moment.
Is Caribou Biosciences stock halal?
No. Caribou Biosciences does not pass our halal screen: its debt is 70% of its market value, at or above the 33% limit. How we check
How has Caribou Biosciences stock done over the past year?
Down 81.8% over the past twelve months, to $0.36. It traded between $0.36 and $2.43 and is 85.1% below its high.
Who are Caribou Biosciences's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Caribou Biosciences's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.